(Q42266669)

English

Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults

scientific article published on June 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

0 references

author name string

Shujun Zhang

1

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Wenxiang Huang

2

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Xiangyang Zhou

3

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Qiquan Zhao

4

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Qun Wang

5

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Bei Jia

6

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

publication date

1 June 2013

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Journal of Medical Virology

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

85

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

1077-1084

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Seroprevalence of neutralizing antibodies to adenovirus type 5 among children in India: implications for recombinant adenovirus-based vaccines

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Adenovirus 36 seropositivity is strongly associated with race and gender, but not obesity, among US military personnel

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Construction of adenoviral vectors

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Replication-defective vector based on a chimpanzee adenovirus

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Humoral immune response to the capsid components of recombinant adenoviruses: routes of immunization modulate virus-induced Ig subclass shifts

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Vitamin A deficiency impairs vaccine-elicited gastrointestinal immunity

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Durable mucosal simian immunodeficiency virus-specific effector memory T lymphocyte responses elicited by recombinant adenovirus vectors in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Immunization with a bivalent adenovirus-vectored tuberculosis vaccine provides markedly improved protection over its monovalent counterpart against pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

The prevalence of antibodies to adenovirus serotype 5 in an adult Indian population and implications for adenovirus vector vaccines

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Viral vectors as vaccine platforms: deployment in sight

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

T cells induced by recombinant chimpanzee adenovirus alone and in prime-boost regimens decrease chimeric EcoHIV/NDK challenge virus load

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Viruses - from pathogens to vaccine carriers

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Adenoviruses as vaccine vectors

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Adenovirus-mediated transfer of human factor IX gene in immunodeficient and normal mice: evidence for prolonged stability and activity of the transgene in liver

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23546

21 January 2018

Identifiers

10.1002/JMV.23546

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42266669&oldid=1940717081"